You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLamotrigine
Accession NumberDB00555  (APRD00570)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer. It is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. Chemically unrelated to other anticonvulsants, lamotrigine has relatively few side-effects and does not require blood monitoring. The exact way lamotrigine works is unknown. [Wikipedia]
Structure
Thumb
Synonyms
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Lamictal
Lamotrigina
Lamotrigine
Lamotriginum
External Identifiers
  • BW 430 C
  • GW 273293
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-lamotrigineTablet150 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Auro-lamotrigineTablet25 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Auro-lamotrigineTablet100 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Dom-lamotrigineTablet100 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lamotrigineTablet150 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lamotrigineTablet25 mgOralDominion PharmacalNot applicableNot applicableCanada
LamictalTablet150 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-29Not applicableUs
LamictalTablet, chewable25 mg/1OralGlaxo Smith Kline Llc1998-09-03Not applicableUs
LamictalTablet150 mg/1OralRebel Distributors Corp1995-01-17Not applicableUs
LamictalTablet5 mgOralGlaxosmithkline Inc1999-06-02Not applicableCanada
LamictalTablet150 mg/1OralGlaxo Smith Kline Llc1995-01-17Not applicableUs
LamictalTablet100 mg/1OralPd Rx Pharmaceuticals, Inc.1995-01-17Not applicableUs
LamictalTablet100 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-29Not applicableUs
LamictalKitGlaxo Smith Kline Llc2003-09-29Not applicableUs
LamictalTablet25 mg/1OralPhysicians Total Care, Inc.2011-02-16Not applicableUs
LamictalTablet200 mg/1OralGlaxo Smith Kline Llc1995-01-18Not applicableUs
LamictalTablet150 mgOralGlaxosmithkline Inc1995-12-31Not applicableCanada
LamictalTablet25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-29Not applicableUs
LamictalTablet25 mg/1OralGlaxo Smith Kline Llc1996-08-15Not applicableUs
LamictalTablet100 mg/1OralPhysicians Total Care, Inc.2008-05-09Not applicableUs
LamictalKitGlaxo Smith Kline Llc2003-09-29Not applicableUs
LamictalTablet100 mgOralGlaxosmithkline Inc1995-12-31Not applicableCanada
LamictalTablet, chewable2 mg/1OralGlaxo Smith Kline Llc2000-10-12Not applicableUs
LamictalTablet200 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-29Not applicableUs
LamictalTablet, chewable5 mg/1OralGlaxo Smith Kline Llc1998-09-04Not applicableUs
LamictalTablet100 mg/1OralGlaxo Smith Kline Llc1995-01-17Not applicableUs
LamictalTablet200 mg/1OralPhysicians Total Care, Inc.2007-05-27Not applicableUs
LamictalTablet25 mg/1OralREMEDYREPACK INC.2016-09-12Not applicableUs
LamictalTablet2 mgOralGlaxosmithkline Inc2001-09-13Not applicableCanada
LamictalTablet25 mgOralGlaxosmithkline Inc1995-12-31Not applicableCanada
LamictalTablet100 mg/1OralRebel Distributors Corp1995-01-17Not applicableUs
Lamictal - Tab 200mgTablet200 mgOralGlaxo Wellcome Inc.1995-12-312001-05-25Canada
Lamictal ODTKitGlaxo Smith Kline Llc2009-06-05Not applicableUs
Lamictal ODTTablet, orally disintegrating200 mg/1OralGlaxo Smith Kline Llc2009-06-05Not applicableUs
Lamictal ODTTablet, orally disintegrating25 mg/1OralGlaxo Smith Kline Llc2009-06-05Not applicableUs
Lamictal ODTKitGlaxo Smith Kline Llc2009-06-05Not applicableUs
Lamictal ODTTablet, orally disintegrating50 mg/1OralGlaxo Smith Kline Llc2009-06-05Not applicableUs
Lamictal ODTTablet, orally disintegrating100 mg/1OralGlaxo Smith Kline Llc2009-06-05Not applicableUs
Lamictal ODTKitGlaxo Smith Kline Llc2009-06-05Not applicableUs
Lamictal XRTablet, film coated, extended release300 mg/1OralGlaxo Smith Kline Llc2011-03-31Not applicableUs
Lamictal XRTablet, film coated, extended release25 mg/1OralGlaxo Smith Kline Llc2009-07-06Not applicableUs
Lamictal XRKitGlaxo Smith Kline Llc2009-07-06Not applicableUs
Lamictal XRTablet, film coated, extended release50 mg/1OralGlaxo Smith Kline Llc2009-07-06Not applicableUs
Lamictal XRTablet, film coated, extended release250 mg/1OralGlaxo Smith Kline Llc2011-08-15Not applicableUs
Lamictal XRKitGlaxo Smith Kline Llc2009-07-06Not applicableUs
Lamictal XRTablet, film coated, extended release100 mg/1OralGlaxo Smith Kline Llc2009-07-06Not applicableUs
Lamictal XRKitGlaxo Smith Kline Llc2009-07-06Not applicableUs
Lamictal XRTablet, film coated, extended release200 mg/1OralGlaxo Smith Kline Llc2009-07-06Not applicableUs
LamotrigineTablet150 mgOralSanis Health Inc2010-02-16Not applicableCanada
LamotrigineTablet25 mgOralSivem Pharmaceuticals Ulc2014-10-08Not applicableCanada
LamotrigineTablet25 mg/1OralRebel Distributors Corp2009-01-27Not applicableUs
LamotrigineTablet100 mgOralSivem Pharmaceuticals Ulc2014-10-08Not applicableCanada
LamotrigineTablet25 mgOralSanis Health Inc2010-02-16Not applicableCanada
LamotrigineTablet100 mg/1OralRebel Distributors Corp2009-01-27Not applicableUs
LamotrigineTablet150 mg/1OralRebel Distributors Corp2009-01-27Not applicableUs
LamotrigineTablet150 mgOralSivem Pharmaceuticals Ulc2014-10-08Not applicableCanada
LamotrigineTablet100 mgOralSanis Health Inc2010-02-16Not applicableCanada
LamotrigineTablet200 mg/1OralRebel Distributors Corp2009-01-27Not applicableUs
Lamotrigine-100Tablet100 mgOralPro Doc Limitee2008-03-08Not applicableCanada
Lamotrigine-150Tablet150 mgOralPro Doc Limitee2008-03-07Not applicableCanada
Lamotrigine-25Tablet25 mgOralPro Doc Limitee2008-03-07Not applicableCanada
Mylan-lamotrigineTablet25 mgOralMylan Pharmaceuticals Ulc2005-04-01Not applicableCanada
Mylan-lamotrigineTablet100 mgOralMylan Pharmaceuticals Ulc2005-04-01Not applicableCanada
Mylan-lamotrigineTablet150 mgOralMylan Pharmaceuticals Ulc2005-04-01Not applicableCanada
Nu-lamotrigineTablet25 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-lamotrigineTablet100 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-lamotrigineTablet150 mgOralNu Pharm IncNot applicableNot applicableCanada
PHL-lamotrigineTablet25 mgOralPharmel IncNot applicableNot applicableCanada
PHL-lamotrigineTablet100 mgOralPharmel IncNot applicableNot applicableCanada
PHL-lamotrigineTablet150 mgOralPharmel IncNot applicableNot applicableCanada
PMS-lamotrigineTablet25 mgOralPharmascience Inc2003-04-14Not applicableCanada
PMS-lamotrigineTablet100 mgOralPharmascience Inc2003-04-14Not applicableCanada
PMS-lamotrigineTablet150 mgOralPharmascience Inc2003-04-14Not applicableCanada
Ratio-lamotrigineTablet150 mgOralTeva Canada Limited2004-01-05Not applicableCanada
Ratio-lamotrigineTablet25 mgOralTeva Canada Limited2002-08-28Not applicableCanada
Ratio-lamotrigineTablet100 mgOralTeva Canada Limited2002-08-30Not applicableCanada
Teva-lamotrigineTablet25 mgOralTeva Canada Limited2004-01-16Not applicableCanada
Teva-lamotrigineTablet100 mgOralTeva Canada Limited2004-01-16Not applicableCanada
Teva-lamotrigineTablet150 mgOralTeva Canada Limited2004-01-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lamotrigineTablet100 mgOralApotex Inc2002-03-18Not applicableCanada
Apo-lamotrigineTablet150 mgOralApotex Inc2002-03-18Not applicableCanada
Apo-lamotrigineTablet25 mgOralApotex Inc2002-03-18Not applicableCanada
LamotrigineTablet100 mg/1OralSandoz Inc2010-01-05Not applicableUs
LamotrigineTablet150 mg/1OralMylan Institutional Inc.2009-06-19Not applicableUs
LamotrigineTablet, film coated, extended release100 mg/1OralWilshire Pharmaceuticals, Inc.2014-03-17Not applicableUs
LamotrigineTablet150 mg/1OralWest ward Pharmaceutical Corp2011-04-19Not applicableUs
LamotrigineTablet, extended release300 mg/1OralDr.Reddy's Laboratories Limited2013-06-20Not applicableUs
LamotrigineTablet100 mg/1OralHikma Pharmaceutical2011-04-19Not applicableUs
LamotrigineTablet, extended release200 mg/1OralTorrent Pharmaceuticals Limited2013-12-23Not applicableUs
LamotrigineTablet25 mg/1OralProficient Rx LP2011-11-01Not applicableUs
LamotrigineTablet100 mg/1OralTYA Pharmaceuticals2011-11-01Not applicableUs
LamotrigineTablet25 mg/1OralAmerican Health Packaging2013-07-05Not applicableUs
LamotrigineTablet25 mg/1OralGlenmark Pharmaceuticals Inc., Usa2012-05-04Not applicableUs
LamotrigineTablet, for suspension25 mg/1OralAlembic Pharmaceuticals Limited2016-01-29Not applicableUs
LamotrigineTablet, orally disintegrating25 mg/1OralImpax Generics2015-01-09Not applicableUs
LamotrigineTablet25 mg/1OralCardinal Health2012-08-24Not applicableUs
LamotrigineTablet, orally disintegrating25 mg/1OralScie Gen Pharmaceuticals, Inc.2015-11-30Not applicableUs
LamotrigineTablet100 mg/1OralAv Kare, Inc.2013-04-03Not applicableUs
LamotrigineTablet150 mg/1OralAurobindo Pharma Limited2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralREMEDYREPACK INC.2013-02-082016-10-13Us
LamotrigineTablet25 mg/1OralLupin Pharmaceuticals, Inc.2011-01-20Not applicableUs
LamotrigineTablet200 mg/1OralUpsher Smith Laboratories, Inc.2011-02-28Not applicableUs
LamotrigineTablet100 mg/1OralAv Pak2015-06-25Not applicableUs
LamotrigineTablet25 mg/1OralREMEDYREPACK INC.2013-02-28Not applicableUs
LamotrigineTablet25 mg/1OralTeva Pharmaceuticals USA Inc2008-07-22Not applicableUs
LamotrigineTablet150 mg/1OralPhysicians Total Care, Inc.2012-01-04Not applicableUs
LamotrigineTablet, extended release200 mg/1OralWockhardt Limited2012-11-29Not applicableUs
LamotrigineTablet100 mg/1OralTorrent Pharmaceuticals Limited2009-01-27Not applicableUs
LamotrigineTablet, chewable25 mg/1OralJubilant Cadista Pharmaceuticals Inc.2011-03-20Not applicableUs
LamotrigineTablet25 mg/1OralMc Kesson Packaging Sevices A Business Unit Of Mc Kesson Corporation2014-02-05Not applicableUs
LamotrigineTablet, chewable25 mg/1OralCadila Healthcare Limited2009-01-23Not applicableUs
LamotrigineTablet150 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-01-27Not applicableUs
LamotrigineTablet200 mg/1OralCipla USA Inc.2010-11-01Not applicableUs
LamotrigineTablet, chewable25 mg/1OralAvera Mc Kennan Hospital2015-04-16Not applicableUs
LamotrigineTablet25 mg/1OralNorth Star Rx Llc2013-01-01Not applicableUs
LamotrigineTablet100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-01-27Not applicableUs
LamotrigineTablet200 mg/1OralUnichem Pharmaceuticals (USA), Inc.2011-11-01Not applicableUs
LamotrigineTablet100 mg/1OralA S Medication Solutions2011-11-01Not applicableUs
LamotrigineTablet25 mg/1OralREMEDYREPACK INC.2011-08-232016-10-21Us
LamotrigineTablet200 mg/1OralAmerican Health Packaging2014-08-28Not applicableUs
LamotrigineTablet150 mg/1OralPreferred Pharmaceuticals, Inc.2014-01-20Not applicableUs
LamotrigineTablet, orally disintegrating200 mg/1OralPar Pharmaceutical Inc.2013-06-02Not applicableUs
LamotrigineTablet25 mg/1OralMylan Pharmaceuticals Inc.2009-01-27Not applicableUs
LamotrigineTablet100 mg/1OralREMEDYREPACK INC.2016-03-04Not applicableUs
LamotrigineTablet, extended release100 mg/1OralREMEDYREPACK INC.2016-10-12Not applicableUs
LamotrigineTablet100 mg/1OralPd Rx Pharmaceuticals, Inc.2009-01-27Not applicableUs
LamotrigineTablet200 mg/1OralPreferred Pharmaceuticals, Inc2016-11-16Not applicableUs
LamotrigineTablet100 mg/1OralUpsher Smith Laboratories, Inc.2009-01-27Not applicableUs
LamotrigineTablet150 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
LamotrigineKitUpsher Smith Laboratories, Inc.2011-02-28Not applicableUs
LamotrigineTablet, extended release200 mg/1OralDr.Reddy's Laboratories Limited2013-06-20Not applicableUs
LamotrigineTablet100 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2009-01-27Not applicableUs
LamotrigineTablet200 mg/1OralREMEDYREPACK INC.2013-04-222016-11-03Us
LamotrigineTablet150 mg/1Oralbryant ranch prepack2009-01-27Not applicableUs
LamotrigineTablet150 mg/1OralCadila Healthcare Limited2009-01-27Not applicableUs
LamotrigineTablet, extended release50 mg/1OralWockhardt USA LLC.2012-11-29Not applicableUs
LamotrigineTablet100 mg/1OralAscend Laboratories, LLC2011-06-22Not applicableUs
LamotrigineTablet, chewable25 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-01-23Not applicableUs
LamotrigineTablet, film coated, extended release200 mg/1OralActavis Pharma, Inc.2016-04-01Not applicableUs
LamotrigineTablet200 mg/1OralREMEDYREPACK INC.2012-07-03Not applicableUs
LamotrigineTablet, orally disintegrating200 mg/1OralDr. Reddy’s Laboratories Inc.2016-06-17Not applicableUs
LamotrigineTablet100 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-09Not applicableUs
LamotrigineTablet200 mg/1OralREMEDYREPACK INC.2011-08-232017-11-11Us
LamotrigineTablet100 mg/1OralREMEDYREPACK INC.2013-04-152016-10-25Us
LamotrigineTablet200 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-07-22Not applicableUs
LamotrigineTablet25 mg/1OralUnit Dose Services2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralREMEDYREPACK INC.2014-05-19Not applicableUs
LamotrigineTablet150 mg/1OralTeva Pharmaceuticals USA Inc2008-07-22Not applicableUs
LamotrigineTablet200 mg/1OralDr.Reddy's Laboratories Limited2009-01-29Not applicableUs
LamotrigineTablet100 mg/1OralClinical Solutions Wholesale, Llc2009-01-27Not applicableUs
LamotrigineTablet, extended release25 mg/1OralTorrent Pharmaceuticals Limited2013-12-23Not applicableUs
LamotrigineTablet200 mg/1OralApotex Corp2009-01-27Not applicableUs
LamotrigineTablet200 mg/1OralAurobindo Pharma Limited2009-01-27Not applicableUs
LamotrigineTablet150 mg/1OralSandoz Inc2010-01-05Not applicableUs
LamotrigineTablet200 mg/1OralMylan Institutional Inc.2009-06-19Not applicableUs
LamotrigineTablet, film coated, extended release200 mg/1OralWilshire Pharmaceuticals, Inc.2014-03-17Not applicableUs
LamotrigineTablet100 mg/1OralWest ward Pharmaceutical Corp2011-04-19Not applicableUs
LamotrigineTablet, extended release25 mg/1OralDr.Reddy's Laboratories Limited2013-06-20Not applicableUs
LamotrigineTablet150 mg/1OralHikma Pharmaceutical2011-04-19Not applicableUs
LamotrigineTablet200 mg/1OralSTAT Rx USA LLC2010-12-07Not applicableUs
LamotrigineTablet100 mg/1Oralbryant ranch prepack2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralCadila Healthcare Limited2009-01-27Not applicableUs
LamotrigineTablet100 mg/1OralAmerican Health Packaging2013-07-05Not applicableUs
LamotrigineTablet100 mg/1OralGlenmark Pharmaceuticals Inc., Usa2012-05-04Not applicableUs
LamotrigineTablet, orally disintegrating25 mg/1OralPar Pharmaceutical Inc.2013-06-02Not applicableUs
LamotrigineTablet, orally disintegrating50 mg/1OralImpax Generics2015-01-09Not applicableUs
LamotrigineTablet100 mg/1OralCardinal Health2012-08-24Not applicableUs
LamotrigineTablet, orally disintegrating50 mg/1OralScie Gen Pharmaceuticals, Inc.2015-11-30Not applicableUs
LamotrigineTablet150 mg/1OralAv Kare, Inc.2013-04-03Not applicableUs
LamotrigineTablet, orally disintegrating25 mg/1OralDr. Reddy’s Laboratories Inc.2016-06-17Not applicableUs
LamotrigineTablet25 mg/1OralAidarex Pharmaceuticals LLC2009-01-27Not applicableUs
LamotrigineTablet150 mg/1OralA S Medication Solutions2011-11-01Not applicableUs
LamotrigineTablet, chewable25 mg/1OralREMEDYREPACK INC.2011-09-08Not applicableUs
LamotrigineTablet100 mg/1OralLupin Pharmaceuticals, Inc.2011-01-20Not applicableUs
LamotrigineTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-07-22Not applicableUs
LamotrigineTablet150 mg/1OralAv Pak2015-06-25Not applicableUs
LamotrigineTablet150 mg/1OralREMEDYREPACK INC.2013-03-27Not applicableUs
LamotrigineTablet, chewable25 mg/1OralTeva Pharmaceuticals USA Inc2006-06-29Not applicableUs
LamotrigineTablet25 mg/1OralDr.Reddy's Laboratories Limited2009-01-29Not applicableUs
LamotrigineTablet, extended release100 mg/1OralWockhardt Limited2012-11-29Not applicableUs
LamotrigineTablet150 mg/1OralTorrent Pharmaceuticals Limited2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralApotex Corp2009-01-27Not applicableUs
LamotrigineTablet, extended release25 mg/1OralWockhardt USA LLC.2012-11-29Not applicableUs
LamotrigineTablet, chewable5 mg/1OralAurobindo Pharma Limited2009-11-04Not applicableUs
LamotrigineTablet200 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralMc Kesson Contract Packaging2011-11-30Not applicableUs
LamotrigineTablet, film coated, extended release25 mg/1OralActavis Pharma, Inc.2016-04-01Not applicableUs
LamotrigineTablet100 mg/1OralNorth Star Rx Llc2013-01-01Not applicableUs
LamotrigineTablet25 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-01-20Not applicableUs
LamotrigineTablet200 mg/1OralCadila Healthcare Limited2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralCipla USA Inc.2010-11-01Not applicableUs
LamotrigineKitPar Pharmaceutical Inc.2013-06-02Not applicableUs
LamotrigineTablet100 mg/1OralMylan Pharmaceuticals Inc.2009-01-27Not applicableUs
LamotrigineTablet150 mg/1OralREMEDYREPACK INC.2016-03-11Not applicableUs
LamotrigineTablet100 mg/1OralProficient Rx LP2010-11-01Not applicableUs
LamotrigineTablet25 mg/1OralPd Rx Pharmaceuticals, Inc.2009-01-27Not applicableUs
LamotrigineTablet, extended release50 mg/1OralREMEDYREPACK INC.2016-11-16Not applicableUs
LamotrigineTablet150 mg/1OralUpsher Smith Laboratories, Inc.2009-01-27Not applicableUs
LamotrigineTablet200 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2009-01-27Not applicableUs
LamotrigineTablet100 mg/1OralPhysicians Total Care, Inc.2008-07-30Not applicableUs
LamotrigineTablet25 mg/1OralUpsher Smith Laboratories, Inc.2011-02-28Not applicableUs
LamotrigineTablet25 mg/1OralCardinal Health2009-12-22Not applicableUs
LamotrigineTablet150 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralUnichem Pharmaceuticals (USA), Inc.2011-11-01Not applicableUs
LamotrigineTablet150 mg/1OralClinical Solutions Wholesale2009-01-27Not applicableUs
LamotrigineTablet, extended release50 mg/1OralTorrent Pharmaceuticals Limited2013-12-23Not applicableUs
LamotrigineTablet100 mg/1OralREMEDYREPACK INC.2015-03-11Not applicableUs
LamotrigineTablet, extended release300 mg/1OralWockhardt USA LLC.2012-11-29Not applicableUs
LamotrigineTablet150 mg/1OralAscend Laboratories, LLC2011-06-22Not applicableUs
LamotrigineTablet, chewable5 mg/1OralGlenmark Pharmaceuticals Inc., Usa2009-02-19Not applicableUs
LamotrigineTablet, film coated, extended release300 mg/1OralActavis Pharma, Inc.2016-04-01Not applicableUs
LamotrigineTablet100 mg/1OralREMEDYREPACK INC.2013-02-22Not applicableUs
LamotrigineTablet150 mg/1OralA S Medication Solutions2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-09Not applicableUs
LamotrigineTablet25 mg/1OralAurobindo Pharma Limited2009-01-27Not applicableUs
LamotrigineTablet200 mg/1OralREMEDYREPACK INC.2013-05-092016-10-21Us
LamotrigineKitSandoz Inc2010-01-05Not applicableUs
LamotrigineTablet25 mg/1OralMylan Institutional Inc.2009-03-02Not applicableUs
LamotrigineTablet, film coated, extended release25 mg/1OralWilshire Pharmaceuticals, Inc.2014-03-17Not applicableUs
LamotrigineTablet200 mg/1OralTeva Pharmaceuticals USA Inc2008-07-22Not applicableUs
LamotrigineTablet, chewable5 mg/1OralDr. Reddy's Laboratories Limited2009-01-29Not applicableUs
LamotrigineTablet, chewable5 mg/1OralCarilion Materials Management2006-08-28Not applicableUs
LamotrigineTablet, orally disintegrating100 mg/1OralScie Gen Pharmaceuticals, Inc.2015-11-30Not applicableUs
LamotrigineTablet200 mg/1OralAv Kare, Inc.2013-04-03Not applicableUs
LamotrigineTablet, chewable5 mg/1OralActavis Pharma, Inc.2009-07-29Not applicableUs
LamotrigineTablet200 mg/1OralSandoz Inc2010-01-05Not applicableUs
LamotrigineTablet25 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
LamotrigineTablet25 mg/1OralWest ward Pharmaceutical Corp2011-04-19Not applicableUs
LamotrigineTablet, extended release50 mg/1OralDr.Reddy's Laboratories Limited2013-06-20Not applicableUs
LamotrigineTablet200 mg/1OralHikma Pharmaceutical2011-04-19Not applicableUs
LamotrigineTablet100 mg/1OralSTAT Rx USA LLC2010-12-07Not applicableUs
LamotrigineTablet25 mg/1Oralbryant ranch prepack2009-01-27Not applicableUs
LamotrigineTablet50 mg/1OralCadila Healthcare Limited2009-01-27Not applicableUs
LamotrigineTablet150 mg/1OralAmerican Health Packaging2013-07-05Not applicableUs
LamotrigineTablet150 mg/1OralGlenmark Pharmaceuticals Inc., Usa2012-05-04Not applicableUs
LamotrigineTablet, orally disintegrating50 mg/1OralPar Pharmaceutical Inc.2013-06-02Not applicableUs
LamotrigineTablet, orally disintegrating100 mg/1OralImpax Generics2015-01-09Not applicableUs
LamotrigineTablet, film coated, extended release100 mg/1OralActavis Pharma, Inc.2016-04-01Not applicableUs
LamotrigineTablet150 mg/1OralNorth Star Rx Llc2013-01-01Not applicableUs
LamotrigineTablet, orally disintegrating50 mg/1OralDr. Reddy’s Laboratories Inc.2016-06-17Not applicableUs
LamotrigineTablet100 mg/1OralAidarex Pharmaceuticals LLC2011-11-01Not applicableUs
LamotrigineTablet, chewable5 mg/1OralMylan Pharmaceuticals Inc.2009-01-262017-02-28Us
LamotrigineTablet100 mg/1OralREMEDYREPACK INC.2013-03-052016-10-13Us
LamotrigineTablet150 mg/1OralLupin Pharmaceuticals, Inc.2011-01-20Not applicableUs
LamotrigineTablet100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-07-22Not applicableUs
LamotrigineTablet200 mg/1OralAv Pak2015-06-25Not applicableUs
LamotrigineTablet100 mg/1OralREMEDYREPACK INC.2013-05-07Not applicableUs
LamotrigineTablet100 mg/1OralTeva Pharmaceuticals USA Inc2008-07-22Not applicableUs
LamotrigineTablet100 mg/1OralDr.Reddy's Laboratories Limited2009-01-29Not applicableUs
LamotrigineTablet, extended release50 mg/1OralWockhardt Limited2012-11-29Not applicableUs
LamotrigineTablet200 mg/1OralTorrent Pharmaceuticals Limited2009-01-27Not applicableUs
LamotrigineTablet100 mg/1OralApotex Corp2009-01-27Not applicableUs
LamotrigineTablet, extended release200 mg/1OralWockhardt USA LLC.2012-11-29Not applicableUs
LamotrigineTablet, chewable25 mg/1OralAurobindo Pharma Limited2009-11-04Not applicableUs
LamotrigineTablet250 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-01-27Not applicableUs
LamotrigineTablet100 mg/1OralMc Kesson Contract Packaging2013-05-13Not applicableUs
LamotrigineTablet100 mg/1OralUpsher Smith Laboratories, Inc.2011-02-28Not applicableUs
LamotrigineTablet100 mg/1OralCardinal Health2009-12-22Not applicableUs
LamotrigineTablet200 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2009-01-27Not applicableUs
LamotrigineTablet100 mg/1OralUnichem Pharmaceuticals (USA), Inc.2011-11-01Not applicableUs
LamotrigineTablet100 mg/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2011-06-08Not applicableUs
LamotrigineTablet250 mg/1OralCadila Healthcare Limited2009-01-27Not applicableUs
LamotrigineTablet50 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-01-27Not applicableUs
LamotrigineTablet100 mg/1OralCipla USA Inc.2010-11-01Not applicableUs
LamotrigineKitPar Pharmaceutical Inc.2013-06-02Not applicableUs
LamotrigineTablet150 mg/1OralMylan Pharmaceuticals Inc.2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralREMEDYREPACK INC.2016-03-11Not applicableUs
LamotrigineTablet100 mg/1OralDIRECT RX2014-01-01Not applicableUs
LamotrigineTablet150 mg/1OralPd Rx Pharmaceuticals, Inc.2009-01-27Not applicableUs
LamotrigineTablet, for suspension5 mg/1OralAlembic Pharmaceuticals Inc.2014-04-11Not applicableUs
LamotrigineTablet200 mg/1OralUpsher Smith Laboratories, Inc.2009-01-27Not applicableUs
LamotrigineTablet, chewable5 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2009-02-04Not applicableUs
LamotrigineTablet200 mg/1OralPhysicians Total Care, Inc.2008-12-05Not applicableUs
LamotrigineTablet, film coated, extended release50 mg/1OralWilshire Pharmaceuticals, Inc.2014-03-17Not applicableUs
LamotrigineTablet200 mg/1OralWest ward Pharmaceutical Corp2011-04-19Not applicableUs
LamotrigineTablet, chewable25 mg/1OralDr. Reddy's Laboratories Limited2009-01-29Not applicableUs
LamotrigineTablet25 mg/1OralHikma Pharmaceutical2011-04-19Not applicableUs
LamotrigineTablet, extended release100 mg/1OralTorrent Pharmaceuticals Limited2013-12-23Not applicableUs
LamotrigineTablet200 mg/1OralDIRECT RX2015-01-01Not applicableUs
LamotrigineTablet25 mg/1OralTYA Pharmaceuticals2011-11-01Not applicableUs
LamotrigineTablet200 mg/1OralAscend Laboratories, LLC2011-06-22Not applicableUs
LamotrigineTablet, chewable25 mg/1OralGlenmark Pharmaceuticals Inc., Usa2009-02-19Not applicableUs
LamotrigineTablet, for suspension5 mg/1OralAlembic Pharmaceuticals Limited2016-01-29Not applicableUs
LamotrigineTablet200 mg/1OralREMEDYREPACK INC.2014-08-25Not applicableUs
LamotrigineTablet100 mg/1OralCardinal Health2009-09-22Not applicableUs
LamotrigineTablet25 mg/1OralA S Medication Solutions2013-01-01Not applicableUs
LamotrigineTablet25 mg/1OralAv Kare, Inc.2013-04-03Not applicableUs
LamotrigineTablet100 mg/1OralAurobindo Pharma Limited2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralREMEDYREPACK INC.2013-04-22Not applicableUs
LamotrigineTablet25 mg/1OralSandoz Inc2010-01-05Not applicableUs
LamotrigineTablet100 mg/1OralMylan Institutional Inc.2009-03-02Not applicableUs
LamotrigineTablet, orally disintegrating100 mg/1OralPar Pharmaceutical Inc.2013-06-02Not applicableUs
LamotrigineTablet, orally disintegrating200 mg/1OralImpax Generics2015-01-09Not applicableUs
LamotrigineTablet25 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
LamotrigineTablet, orally disintegrating200 mg/1OralScie Gen Pharmaceuticals, Inc.2015-11-30Not applicableUs
LamotrigineTablet200 mg/1OralPd Rx Pharmaceuticals, Inc.2009-01-27Not applicableUs
LamotrigineTablet, chewable25 mg/1OralActavis Pharma, Inc.2009-07-29Not applicableUs
LamotrigineTablet25 mg/1OralUpsher Smith Laboratories, Inc.2009-01-27Not applicableUs
LamotrigineTablet100 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
LamotrigineKitUpsher Smith Laboratories, Inc.2011-02-28Not applicableUs
LamotrigineTablet, extended release100 mg/1OralDr.Reddy's Laboratories Limited2013-06-20Not applicableUs
LamotrigineTablet25 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2009-01-27Not applicableUs
LamotrigineTablet100 mg/1OralREMEDYREPACK INC.2011-12-132016-11-02Us
LamotrigineTablet25 mg/1Oralbryant ranch prepack2009-01-27Not applicableUs
LamotrigineTablet100 mg/1OralCadila Healthcare Limited2009-01-27Not applicableUs
LamotrigineTablet, chewable25 mg/1OralAmerican Health Packaging2011-06-17Not applicableUs
LamotrigineTablet200 mg/1OralGlenmark Pharmaceuticals Inc., Usa2012-05-04Not applicableUs
LamotrigineTablet, chewable5 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-01-23Not applicableUs
LamotrigineTablet, film coated, extended release50 mg/1OralActavis Pharma, Inc.2016-04-01Not applicableUs
LamotrigineTablet200 mg/1OralNorth Star Rx Llc2013-01-01Not applicableUs
LamotrigineTablet, orally disintegrating100 mg/1OralDr. Reddy’s Laboratories Inc.2016-06-17Not applicableUs
LamotrigineTablet200 mg/1OralAidarex Pharmaceuticals LLC2009-01-27Not applicableUs
LamotrigineTablet, chewable25 mg/1OralMylan Pharmaceuticals Inc.2009-01-262017-02-28Us
LamotrigineTablet25 mg/1OralREMEDYREPACK INC.2013-05-102016-10-28Us
LamotrigineTablet200 mg/1OralLupin Pharmaceuticals, Inc.2011-01-20Not applicableUs
LamotrigineTablet150 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-07-22Not applicableUs
LamotrigineTablet100 mg/1OralUnit Dose Services2009-01-27Not applicableUs
LamotrigineTablet150 mg/1OralREMEDYREPACK INC.2014-03-04Not applicableUs
LamotrigineTablet, chewable5 mg/1OralTeva Pharmaceuticals USA Inc2006-08-28Not applicableUs
LamotrigineTablet150 mg/1OralDr.Reddy's Laboratories Limited2009-01-29Not applicableUs
LamotrigineTablet, extended release300 mg/1OralWockhardt Limited2012-11-29Not applicableUs
LamotrigineKitTorrent Pharmaceuticals Limited2009-09-14Not applicableUs
LamotrigineTablet150 mg/1OralApotex Corp2009-01-27Not applicableUs
LamotrigineTablet, extended release100 mg/1OralWockhardt USA LLC.2012-11-29Not applicableUs
LamotrigineTablet25 mg/1OralAscend Laboratories, LLC2011-06-22Not applicableUs
LamotrigineTablet25 mg/1OralTorrent Pharmaceuticals Limited2009-01-27Not applicableUs
LamotrigineTablet, chewable25 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2009-02-04Not applicableUs
LamotrigineTablet25 mg/1OralPhysicians Total Care, Inc.2009-12-09Not applicableUs
LamotrigineTablet150 mg/1OralUpsher Smith Laboratories, Inc.2011-02-28Not applicableUs
LamotrigineTablet, extended release25 mg/1OralWockhardt Limited2012-11-29Not applicableUs
LamotrigineTablet, chewable5 mg/1OralJubilant Cadista Pharmaceuticals Inc.2011-03-20Not applicableUs
LamotrigineTablet150 mg/1OralUnichem Pharmaceuticals (USA), Inc.2011-11-01Not applicableUs
LamotrigineTablet200 mg/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2011-06-08Not applicableUs
LamotrigineTablet, chewable5 mg/1OralCadila Healthcare Limited2009-01-23Not applicableUs
LamotrigineTablet100 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-01-27Not applicableUs
LamotrigineTablet150 mg/1OralCipla USA Inc.2010-11-01Not applicableUs
LamotrigineKitPar Pharmaceutical Inc.2013-06-02Not applicableUs
LamotrigineTablet200 mg/1OralMylan Pharmaceuticals Inc.2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-01-27Not applicableUs
LamotrigineTablet25 mg/1OralA S Medication Solutions2011-11-01Not applicableUs
LamotrigineTablet150 mg/1OralREMEDYREPACK INC.2011-07-292016-10-13Us
LamotrigineTablet, for suspension25 mg/1OralAlembic Pharmaceuticals Inc.2014-04-11Not applicableUs
LamotrigineTablet25 mg/1OralAv Pak2015-06-25Not applicableUs
Lamotrigine Extended ReleaseTablet200 mg/1OralPar Pharmaceutical Inc.2013-01-18Not applicableUs
Lamotrigine Extended ReleaseTablet25 mg/1OralPar Pharmaceutical Inc.2013-01-18Not applicableUs
Lamotrigine Extended ReleaseTablet250 mg/1OralPar Pharmaceutical Inc.2013-01-18Not applicableUs
Lamotrigine Extended ReleaseTablet50 mg/1OralPar Pharmaceutical Inc.2013-01-18Not applicableUs
Lamotrigine Extended ReleaseTablet300 mg/1OralPar Pharmaceutical Inc.2013-01-18Not applicableUs
Lamotrigine Extended ReleaseTablet100 mg/1OralPar Pharmaceutical Inc.2013-01-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ConvulsanActavis
CrisometJuste
DafexPhoenix
DaksolPharmavita
DanoptinPliva
DezepilRafarm
ElmendosGlaxoSmithKline
EpilepaxIvax
EpimilIvax
EpiralZentiva
EpitecCipla Medpro
EpitrigineActavis
LabilenoGlaxoSmithKline
LambipolGlaxoSmithKline
LamectPharmaSwiss
LameptilSandoz
Lameptil SSandoz
LametecVitalchem
LamezIntas
Lamictal CDGlaxoSmithKline
LamictinGlaxoSmithKline
LamotrixGlenmark
LarigRowex
MedotriginMedochemie
MogineDouglas
TrimolepPsicofarma
TrogineRanbaxy
XebarinDr Reddys
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIU3H27498KS
CAS number84057-84-1
WeightAverage: 256.091
Monoisotopic: 255.007850663
Chemical FormulaC9H7Cl2N5
InChI KeyPYZRQGJRPPTADH-UHFFFAOYSA-N
InChI
InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
IUPAC Name
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
SMILES
NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Pharmacology
IndicationFor the adjunctive treatment of partial seizures in epilepsy and generalized seizures of Lennox-Gastaut syndrome. Also for the maintenance treatment of bipolar I disorder and depression.
Structured Indications
PharmacodynamicsLamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically unrelated to existing antiepileptic drugs. Lamotrigine is also used in the treatment of depression and bipolar disorder. Lamotrigine is thought to exert its anticonvulsant effect by stabilizing presynaptic neuronal membranes. Lamotrigine inhibits sodium currents by selectively binding to the inactivated state of the sodium channel and subsequently suppresses the release of the excilatory amino acid, glutamate.
Mechanism of actionOne proposed mechanism of action of Lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. in vitro pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels and/or calcium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate). Studies on lamotrigine show binding to sodium channels similar to local anesthetics.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium channel protein type 2 subunit alphaProteinunknown
inhibitor
HumanQ99250 details
Related Articles
Absorption98%
Volume of distribution
  • 0.9 to 1.3 L/kg
Protein binding55%
Metabolism

Hepatic

SubstrateEnzymesProduct
Lamotrigine
lamotrigine-2-N-glucuronideDetails
Route of eliminationNot Available
Half life25 +/- 10 hours (healthy individuals); 42.9 hours (chronic renal failure)
Clearance
  • Apparent plasma cl=0.44 mL/min/kg [healthy volunteers taking single-dose LAMICTAL]
  • Apparent plasma cl=0.58 mL/min/kg [healthy volunteers taking multiple-dose LAMICTAL]
  • Apparent plasma cl=0.30 mL/min/kg [healthy volunteers taking valproate and single-dose LAMICTAL]
  • Apparent plasma cl=0.18 mL/min/kg [healthy volunteers taking valproate and multiple-dose LAMICTAL]
  • Apparent plasma cl=1.1 mL/min/kg [Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone plus valproate and single-dose LAMICTAL]
  • Apparent plasma cl=1.12 mL/min/kg [Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone plus valproate and multiple-dose LAMICTAL]
ToxicityLD50=250 (mg/kg) (in rat, mice); LD50>640 orally (mg/kg) (in rat, mice) (Sawyer). Symptoms of overdose include decreased level of consciousness, coma, delayed heartbeat, increased seizures, lack of coordination, and rolling eyeballs.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Lamotrigine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Lamotrigine.Vet Approved
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Lamotrigine.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Lamotrigine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Lamotrigine.Approved
AcetaminophenThe serum concentration of Lamotrigine can be increased when it is combined with Acetaminophen.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Lamotrigine.Investigational
AfatinibThe serum concentration of Lamotrigine can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lamotrigine.Approved, Investigational
AlbendazoleThe serum concentration of Lamotrigine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Lamotrigine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Lamotrigine can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Lamotrigine.Vet Approved
AlfentanilThe serum concentration of Lamotrigine can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Lamotrigine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Lamotrigine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lamotrigine.Approved, Illicit, Investigational
AmantadineThe serum concentration of Lamotrigine can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Lamotrigine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Lamotrigine can be decreased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Lamotrigine.Approved, Investigational
AmitriptylineThe serum concentration of Lamotrigine can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Lamotrigine can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Lamotrigine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lamotrigine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Lamotrigine.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lamotrigine.Approved, Investigational
AmprenavirThe serum concentration of Lamotrigine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Lamotrigine can be increased when it is combined with Amsacrine.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Lamotrigine.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Lamotrigine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lamotrigine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Lamotrigine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Lamotrigine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Lamotrigine.Approved
AstemizoleThe serum concentration of Lamotrigine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Lamotrigine can be decreased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Lamotrigine can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Lamotrigine can be increased when it is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Atosiban.Approved
Atracurium besylateLamotrigine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Lamotrigine.Vet Approved
AzelastineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Lamotrigine can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Lamotrigine can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Lamotrigine.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Lamotrigine.Experimental
BarbexacloneThe serum concentration of Lamotrigine can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Lamotrigine can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Lamotrigine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Lamotrigine.Approved
BepridilThe serum concentration of Lamotrigine can be increased when it is combined with Bepridil.Approved, Withdrawn
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Lamotrigine.Approved
BiperidenThe serum concentration of Lamotrigine can be increased when it is combined with Biperiden.Approved
BosutinibThe serum concentration of Lamotrigine can be increased when it is combined with Bosutinib.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Lamotrigine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lamotrigine.Approved, Illicit
BromocriptineThe serum concentration of Lamotrigine can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Lamotrigine.Approved, Withdrawn
BucindololBucindolol may increase the hypotensive activities of Lamotrigine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lamotrigine.Approved, Investigational
BuprenorphineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Lamotrigine can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lamotrigine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Lamotrigine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Lamotrigine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Lamotrigine.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Lamotrigine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Lamotrigine.Approved, Illicit
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Lamotrigine.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lamotrigine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Lamotrigine can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Lamotrigine can be increased when it is combined with Caffeine.Approved
CalciumThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CanagliflozinThe serum concentration of Lamotrigine can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Lamotrigine can be increased when it is combined with Candesartan.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Lamotrigine.Withdrawn
CaptoprilThe serum concentration of Lamotrigine can be increased when it is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbinoxamine.Approved
CarbomycinThe metabolism of Lamotrigine can be decreased when combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Lamotrigine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lamotrigine.Approved
CarvedilolThe serum concentration of Lamotrigine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Lamotrigine.Approved
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Lamotrigine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Lamotrigine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lamotrigine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lamotrigine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Lamotrigine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lamotrigine.Approved
ChloroquineThe serum concentration of Lamotrigine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Lamotrigine can be decreased when it is combined with Chlorotrianisene.Withdrawn
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Lamotrigine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Lamotrigine can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Lamotrigine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Lamotrigine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lamotrigine.Approved
CholesterolThe serum concentration of Lamotrigine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Lamotrigine can be decreased when it is combined with Cholic Acid.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Lamotrigine.Approved, Investigational
CilazaprilThe serum concentration of Lamotrigine can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Lamotrigine can be increased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lamotrigine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Lamotrigine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Lamotrigine can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Lamotrigine can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Lamotrigine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Lamotrigine.Approved, Illicit
ClofazimineThe serum concentration of Lamotrigine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Lamotrigine.Investigational
ClomipramineThe serum concentration of Lamotrigine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lamotrigine.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lamotrigine.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Lamotrigine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lamotrigine.Approved
CobicistatThe serum concentration of Lamotrigine can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Lamotrigine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Lamotrigine.Approved, Illicit
ColchicineThe serum concentration of Lamotrigine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Lamotrigine can be increased when it is combined with Colforsin.Experimental
Conjugated Equine EstrogensThe serum concentration of Lamotrigine can be decreased when it is combined with Conjugated Equine Estrogens.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Lamotrigine.Investigational
CrizotinibThe serum concentration of Lamotrigine can be increased when it is combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lamotrigine.Approved
CyclophosphamideThe serum concentration of Lamotrigine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lamotrigine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Lamotrigine.Approved
DaclatasvirThe serum concentration of Lamotrigine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Lamotrigine can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lamotrigine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Lamotrigine.Investigational
DasatinibThe serum concentration of Lamotrigine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Lamotrigine can be decreased when it is combined with Daunorubicin.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Lamotrigine.Experimental
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Lamotrigine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lamotrigine.Approved
DesipramineThe serum concentration of Lamotrigine can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Lamotrigine can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Lamotrigine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Lamotrigine.Vet Approved
DexamethasoneThe serum concentration of Lamotrigine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lamotrigine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lamotrigine.Approved, Vet Approved
DextromethorphanThe serum concentration of Lamotrigine can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Lamotrigine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lamotrigine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Lamotrigine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Lamotrigine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Lamotrigine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Lamotrigine can be decreased when it is combined with Dienestrol.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Lamotrigine.Approved
DiethylstilbestrolThe serum concentration of Lamotrigine can be decreased when it is combined with Diethylstilbestrol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Difenoxin.Approved, Illicit
DigoxinThe serum concentration of Lamotrigine can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lamotrigine.Approved, Illicit
DihydroergotamineThe serum concentration of Lamotrigine can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lamotrigine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lamotrigine.Experimental, Illicit
DiltiazemThe serum concentration of Lamotrigine can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lamotrigine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lamotrigine.Approved, Illicit
DipyridamoleThe serum concentration of Lamotrigine can be increased when it is combined with Dipyridamole.Approved
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Lamotrigine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Lamotrigine.Vet Approved
DoxazosinThe serum concentration of Lamotrigine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Lamotrigine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Lamotrigine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Lamotrigine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Illicit
DronedaroneThe serum concentration of Lamotrigine can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Lamotrigine.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Lamotrigine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lamotrigine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Lamotrigine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Lamotrigine.Experimental
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Lamotrigine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Lamotrigine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Lamotrigine.Approved
ElbasvirThe serum concentration of Lamotrigine can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Lamotrigine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Lamotrigine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Lamotrigine.Approved, Investigational
EnzalutamideThe serum concentration of Lamotrigine can be increased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Lamotrigine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Lamotrigine can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Lamotrigine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lamotrigine.Approved, Illicit
EstradiolThe serum concentration of Lamotrigine can be decreased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Lamotrigine can be decreased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Lamotrigine can be decreased when it is combined with Estriol.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Lamotrigine can be decreased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Lamotrigine can be decreased when it is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Lamotrigine can be decreased when it is combined with Estrone sulfate.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lamotrigine.Approved
EthanolLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lamotrigine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Lamotrigine can be decreased when it is combined with Ethinyl Estradiol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lamotrigine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Lamotrigine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lamotrigine.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lamotrigine.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Lamotrigine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Lamotrigine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Lamotrigine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Lamotrigine.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Lamotrigine.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Lamotrigine can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Lamotrigine.Illicit, Vet Approved
EtravirineThe serum concentration of Lamotrigine can be increased when it is combined with Etravirine.Approved
EzogabineThe serum concentration of Lamotrigine can be decreased when it is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Felbamate.Approved
FelodipineThe serum concentration of Lamotrigine can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lamotrigine.Approved, Illicit, Withdrawn
FentanylThe serum concentration of Lamotrigine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Lamotrigine can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Lamotrigine can be increased when it is combined with Fidaxomicin.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flibanserin.Approved
FluconazoleThe serum concentration of Lamotrigine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Lamotrigine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Lamotrigine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lamotrigine.Approved, Illicit
FluoxetineThe serum concentration of Lamotrigine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Lamotrigine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Lamotrigine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Lamotrigine can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lamotrigine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluticasone Propionate.Approved
FluvoxamineThe serum concentration of Lamotrigine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Lamotrigine can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Lamotrigine.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lamotrigine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Lamotrigine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lamotrigine.Approved, Illicit
GefitinibThe serum concentration of Lamotrigine can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Lamotrigine can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Gepirone.Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Lamotrigine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Lamotrigine.Approved, Illicit
GlyburideThe serum concentration of Lamotrigine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Lamotrigine can be increased when it is combined with Glycerol.Experimental
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Lamotrigine.Experimental
Gramicidin DThe serum concentration of Lamotrigine can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Lamotrigine can be increased when it is combined with Grepafloxacin.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Lamotrigine.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Lamotrigine.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Lamotrigine can be increased when it is combined with Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Lamotrigine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lamotrigine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Lamotrigine.Approved, Illicit
HexestrolThe serum concentration of Lamotrigine can be decreased when it is combined with Hexestrol.Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Lamotrigine.Approved
HexobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Hexobarbital.Approved
HydrocodoneLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Lamotrigine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lamotrigine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
IdelalisibThe serum concentration of Lamotrigine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Iloperidone.Approved
ImatinibThe serum concentration of Lamotrigine can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Lamotrigine can be increased when it is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Lamotrigine can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Lamotrigine can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminIndoramin may increase the hypotensive activities of Lamotrigine.Withdrawn
IsavuconazoniumThe serum concentration of Lamotrigine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Lamotrigine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lamotrigine.Approved, Vet Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Lamotrigine.Approved, Investigational
IvacaftorThe serum concentration of Lamotrigine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Lamotrigine can be increased when it is combined with Ivermectin.Approved, Vet Approved
JosamycinThe metabolism of Lamotrigine can be decreased when combined with Josamycin.Approved
KetamineThe serum concentration of Lamotrigine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lamotrigine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Lamotrigine.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Lamotrigine.Approved, Investigational
KitasamycinThe metabolism of Lamotrigine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Lamotrigine.Approved
LansoprazoleThe serum concentration of Lamotrigine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lamotrigine can be increased when it is combined with Lapatinib.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lamotrigine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Lamotrigine can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lamotrigine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levomilnacipran.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Lamotrigine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lamotrigine.Approved
LevothyroxineThe serum concentration of Lamotrigine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Lamotrigine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Lamotrigine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Lamotrigine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Lamotrigine can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Lamotrigine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Lamotrigine.Illicit
LomitapideThe serum concentration of Lamotrigine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Lamotrigine can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Lamotrigine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Lamotrigine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lamotrigine.Approved
LosartanThe serum concentration of Lamotrigine can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Lamotrigine can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lamotrigine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Lamotrigine.Investigational
LumacaftorThe serum concentration of Lamotrigine can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lamotrigine.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Lamotrigine.Investigational
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium salicylate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Vet Approved
MaprotilineThe serum concentration of Lamotrigine can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Lamotrigine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Lamotrigine.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lamotrigine.Approved, Investigational
MefloquineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Mefloquine.Approved
Megestrol acetateThe serum concentration of Lamotrigine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Lamotrigine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Lamotrigine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lamotrigine.Approved, Vet Approved
MeprobamateThe serum concentration of Lamotrigine can be increased when it is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lamotrigine.Approved
MestranolThe serum concentration of Lamotrigine can be decreased when it is combined with Mestranol.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Metaxalone.Approved
MetforminThe serum concentration of Metformin can be increased when it is combined with Lamotrigine.Approved
MethadoneThe serum concentration of Lamotrigine can be increased when it is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Lamotrigine.Approved, Illicit
MethallenestrilThe serum concentration of Lamotrigine can be decreased when it is combined with Methallenestril.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Lamotrigine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Lamotrigine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lamotrigine.Approved, Vet Approved
MethohexitalThe serum concentration of Lamotrigine can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lamotrigine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methsuximide.Approved
MethylphenobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Methylphenobarbital.Approved
MetoprololThe serum concentration of Lamotrigine can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineLamotrigine may increase the sedative activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Lamotrigine.Experimental
MianserinThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Mianserin.Approved
MibefradilThe serum concentration of Lamotrigine can be increased when it is combined with Mibefradil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Lamotrigine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Lamotrigine.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Lamotrigine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Lamotrigine can be decreased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Milnacipran.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Lamotrigine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
MirtazapineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Lamotrigine can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Lamotrigine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumLamotrigine may increase the neuromuscular blocking activities of Mivacurium.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Lamotrigine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Lamotrigine.Vet Approved
MorphineThe serum concentration of Lamotrigine can be increased when it is combined with Morphine.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Lamotrigine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
NafcillinThe metabolism of Lamotrigine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lamotrigine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lamotrigine.Approved
NaltrexoneThe serum concentration of Lamotrigine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Lamotrigine can be increased when it is combined with Naringenin.Experimental
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Lamotrigine.Approved
NefazodoneThe serum concentration of Lamotrigine can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lamotrigine can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Lamotrigine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Lamotrigine can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Lamotrigine can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Lamotrigine can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Lamotrigine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Lamotrigine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Lamotrigine can be increased when it is combined with Nitrendipine.Approved
NitroprussideLamotrigine may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lamotrigine.Approved, Vet Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Lamotrigine.Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Lamotrigine.Approved
NorethisteroneThe serum concentration of Lamotrigine can be decreased when it is combined with Norethisterone.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Lamotrigine.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Lamotrigine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Lamotrigine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lamotrigine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Lamotrigine.Approved, Vet Approved
OlanzapineLamotrigine may increase the sedative activities of Olanzapine.Approved, Investigational
OleandomycinThe metabolism of Lamotrigine can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Lamotrigine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lamotrigine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Lamotrigine.Approved, Illicit
OrlistatThe serum concentration of Lamotrigine can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Lamotrigine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lamotrigine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxetacaine.Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Lamotrigine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lamotrigine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lamotrigine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lamotrigine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lamotrigine.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Lamotrigine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Lamotrigine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Lamotrigine.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lamotrigine.Approved
Palmitic AcidThe serum concentration of Lamotrigine can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Lamotrigine can be increased when it is combined with Pantoprazole.Approved
ParaldehydeLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe serum concentration of Lamotrigine can be increased when it is combined with Paroxetine.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Lamotrigine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lamotrigine.Approved, Vet Approved
PentobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
PerazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Perazine.Investigational
PerindoprilThe serum concentration of Lamotrigine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Lamotrigine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lamotrigine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lamotrigine.Approved
PhenobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Lamotrigine.Approved
PhenytoinThe serum concentration of Lamotrigine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Lamotrigine can be increased when it is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Lamotrigine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Lamotrigine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Lamotrigine can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Lamotrigine.Approved, Investigational, Vet Approved
PramipexoleLamotrigine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Lamotrigine.Approved
PravastatinThe serum concentration of Lamotrigine can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Lamotrigine.Approved, Illicit
PrazosinThe serum concentration of Lamotrigine can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Lamotrigine can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lamotrigine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Lamotrigine.Approved
PrimidoneThe serum concentration of Lamotrigine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Lamotrigine can be increased when it is combined with Probenecid.Approved
ProcainamideThe serum concentration of Procainamide can be increased when it is combined with Lamotrigine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Lamotrigine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lamotrigine.Approved, Vet Approved
ProgesteroneThe serum concentration of Lamotrigine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Lamotrigine.Approved, Vet Approved
PromethazineThe serum concentration of Lamotrigine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Lamotrigine can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lamotrigine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Lamotrigine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Lamotrigine.Approved
PropranololThe serum concentration of Lamotrigine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Lamotrigine can be increased when it is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Lamotrigine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Lamotrigine.Approved, Illicit
QuercetinThe serum concentration of Lamotrigine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lamotrigine.Approved
QuinacrineThe serum concentration of Lamotrigine can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Lamotrigine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Lamotrigine can be increased when it is combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Raclopride.Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Lamotrigine.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Lamotrigine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Lamotrigine can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumLamotrigine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
ReboxetineThe serum concentration of Lamotrigine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Lamotrigine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lamotrigine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lamotrigine.Approved, Withdrawn
ReserpineThe serum concentration of Lamotrigine can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Lamotrigine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe metabolism of Lamotrigine can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Lamotrigine can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Lamotrigine can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Lamotrigine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Lamotrigine can be decreased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Lamotrigine can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Lamotrigine.Vet Approved
RopiniroleLamotrigine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lamotrigine.Approved
RotigotineLamotrigine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lamotrigine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lamotrigine.Experimental
Sage 547The risk or severity of adverse effects can be increased when Lamotrigine is combined with Sage 547.Investigational
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Lamotrigine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lamotrigine.Approved, Vet Approved
SaquinavirThe serum concentration of Lamotrigine can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Lamotrigine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Lamotrigine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Lamotrigine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Lamotrigine.Approved, Withdrawn
SertralineThe serum concentration of Lamotrigine can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lamotrigine.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Lamotrigine.Approved
SimeprevirThe serum concentration of Lamotrigine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Lamotrigine can be increased when it is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Lamotrigine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Lamotrigine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
SolithromycinThe metabolism of Lamotrigine can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Lamotrigine can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Lamotrigine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Lamotrigine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Lamotrigine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Lamotrigine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lamotrigine.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Lamotrigine.Approved
SulfinpyrazoneThe serum concentration of Lamotrigine can be increased when it is combined with Sulfinpyrazone.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lamotrigine.Approved
SumatriptanThe serum concentration of Lamotrigine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Lamotrigine can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Lamotrigine can be decreased when it is combined with Synthetic Conjugated Estrogens, A.Approved
TacrineThe serum concentration of Lamotrigine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Lamotrigine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Lamotrigine can be decreased when it is combined with Tamoxifen.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Lamotrigine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Lamotrigine can be increased when it is combined with Taurocholic Acid.Experimental
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Lamotrigine.Approved
TelithromycinThe metabolism of Lamotrigine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Lamotrigine can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lamotrigine.Approved
TemsirolimusThe serum concentration of Lamotrigine can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Lamotrigine can be increased when it is combined with Terazosin.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Lamotrigine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Lamotrigine.Approved
TerfenadineThe serum concentration of Lamotrigine can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Lamotrigine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Lamotrigine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Lamotrigine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Lamotrigine.Investigational
ThalidomideLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe serum concentration of Lamotrigine can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe serum concentration of Lamotrigine can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lamotrigine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lamotrigine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Lamotrigine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Lamotrigine can be increased when it is combined with Ticagrelor.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Lamotrigine.Vet Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Lamotrigine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lamotrigine.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Lamotrigine.Approved, Vet Approved
TolvaptanThe serum concentration of Lamotrigine can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Lamotrigine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lamotrigine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lamotrigine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lamotrigine.Approved
TrazodoneThe serum concentration of Lamotrigine can be decreased when it is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lamotrigine.Approved
TrifluoperazineThe serum concentration of Lamotrigine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Lamotrigine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Lamotrigine.Experimental
TrimethoprimThe serum concentration of Lamotrigine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Lamotrigine.Approved, Investigational
TrimipramineThe serum concentration of Lamotrigine can be increased when it is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Lamotrigine.Approved
TroleandomycinThe metabolism of Lamotrigine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Lamotrigine can be decreased when combined with Tylosin.Vet Approved
Uc1010The risk or severity of adverse effects can be increased when Lamotrigine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Lamotrigine.Approved, Investigational
VenlafaxineThe serum concentration of Lamotrigine can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Lamotrigine can be decreased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vigabatrin.Approved
VinblastineThe serum concentration of Lamotrigine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Lamotrigine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Lamotrigine can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Lamotrigine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lamotrigine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Lamotrigine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lamotrigine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ziconotide.Approved
ZimelidineThe serum concentration of Lamotrigine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Lamotrigine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Lamotrigine.Vet Approved
ZolpidemLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lamotrigine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Lamotrigine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lamotrigine.Approved, Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Grahame Roy Lee, “Process for the preparation of lamotrigine.” U.S. Patent US5925755, issued January, 1981.

US5925755
General References
  1. Backonja M: Neuromodulating drugs for the symptomatic treatment of neuropathic pain. Curr Pain Headache Rep. 2004 Jun;8(3):212-6. [PubMed:15115640 ]
  2. Barbosa L, Berk M, Vorster M: A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003 Apr;64(4):403-7. [PubMed:12716240 ]
  3. Jensen TS: Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6 Suppl A:61-8. [PubMed:11888243 ]
  4. Pappagallo M: Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther. 2003 Oct;25(10):2506-38. [PubMed:14667954 ]
  5. Tehrani SP, Daryaafzoon M, Bakhtiarian A, Ejtemaeemehr S, Sahraei H: The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9. [PubMed:19579915 ]
External Links
ATC CodesN03AX09
AHFS Codes
  • 28:12.92
PDB EntriesNot Available
FDA labelDownload (3.15 MB)
MSDSDownload (28.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9382
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.7155
P-glycoprotein inhibitor INon-inhibitor0.911
P-glycoprotein inhibitor IINon-inhibitor0.9604
Renal organic cation transporterNon-inhibitor0.8176
CYP450 2C9 substrateNon-substrate0.9162
CYP450 2D6 substrateNon-substrate0.9055
CYP450 3A4 substrateNon-substrate0.6862
CYP450 1A2 substrateNon-inhibitor0.611
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.7007
CYP450 2C19 inhibitorNon-inhibitor0.8594
CYP450 3A4 inhibitorNon-inhibitor0.7678
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5515
Ames testNon AMES toxic0.8202
CarcinogenicityNon-carcinogens0.7895
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7556 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9168
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Aurobindo pharma ltd
  • Dr reddys laboratories ltd
  • Glenmark generics ltd
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Smithkline beecham corp
  • Smithkline beecham corp dba glaxosmithkline
  • Apotex inc
  • Cadista pharmaceuticals inc
  • Lupin ltd
  • Matrix laboratories ltd
  • Roxane laboratories inc
  • Torrent pharmaceuticals ltd
  • Upsher smith laboratories inc
  • Wockhardt ltd
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral150 mg
TabletOral2 mg
TabletOral25 mg
TabletOral5 mg
Tablet, chewableOral2 mg/1
TabletOral200 mg
Tablet, orally disintegratingOral100 mg/1
Tablet, orally disintegratingOral200 mg/1
Tablet, orally disintegratingOral25 mg/1
Tablet, orally disintegratingOral50 mg/1
Kit
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral25 mg/1
Tablet, film coated, extended releaseOral250 mg/1
Tablet, film coated, extended releaseOral300 mg/1
Tablet, film coated, extended releaseOral50 mg/1
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral200 mg/1
TabletOral25 mg/1
Tablet, chewableOral25 mg/1
Tablet, chewableOral5 mg/1
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral25 mg/1
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral50 mg/1
Tablet, for suspensionOral25 mg/1
Tablet, for suspensionOral5 mg/1
TabletOral250 mg/1
TabletOral300 mg/1
TabletOral50 mg/1
Prices
Unit descriptionCostUnit
LaMICtal Starter 98 25 (84)-100(14)mg Kit Box556.69USD box
LaMICtal XR 200 mg 24 Hour tablet12.11USD tablet
Lamictal xr 200 mg tablet11.65USD tablet
LaMICtal XR 100 mg 24 Hour tablet11.36USD tablet
Lamictal xr 100 mg tablet10.92USD tablet
Lamictal xr 50 mg tablet10.2USD tablet
Lamictal 200 mg tablet7.44USD tablet
Lamictal odt start kt (orange)7.28USD tablet
Lamictal xr start kit (orange)7.28USD tablet
Lamictal odt 200 mg tablet6.95USD tablet
Lamictal odt 100 mg tablet5.82USD tablet
Lamotrigine 200 mg tablet5.78USD tablet
LaMICtal 25 mg Chew Tabs5.63USD tab
Lamictal odt 50 mg tablet5.46USD tablet
Lamictal tab start kit (green)5.46USD tablet
Lamictal 150 mg tablet5.38USD tablet
Lamictal odt 25 mg tablet5.1USD tablet
Lamictal xr 25 mg tablet5.1USD tablet
Lamictal 100 mg tablet4.72USD tablet
Lamotrigine tablet starter kit4.24USD tablet
Lamotrigine 150 mg tablet3.98USD tablet
Lamictal 25 mg tablet3.78USD tablet
Lamotrigine 100 mg tablet3.52USD tablet
LamoTRIgine 25 mg Chew Tabs3.33USD tab
LamoTRIgine 5 mg Chew Tabs3.18USD tab
Lamotrigine 25 mg tablet2.9USD tablet
Apo-Lamotrigine 150 mg Tablet1.31USD tablet
Mylan-Lamotrigine 150 mg Tablet1.31USD tablet
Novo-Lamotrigine 150 mg Tablet1.31USD tablet
Pms-Lamotrigine 150 mg Tablet1.31USD tablet
Ratio-Lamotrigine 150 mg Tablet1.31USD tablet
Apo-Lamotrigine 100 mg Tablet0.88USD tablet
Mylan-Lamotrigine 100 mg Tablet0.88USD tablet
Novo-Lamotrigine 100 mg Tablet0.88USD tablet
Pms-Lamotrigine 100 mg Tablet0.88USD tablet
Ratio-Lamotrigine 100 mg Tablet0.88USD tablet
Apo-Lamotrigine 25 mg Tablet0.22USD tablet
Mylan-Lamotrigine 25 mg Tablet0.22USD tablet
Novo-Lamotrigine 25 mg Tablet0.22USD tablet
Pms-Lamotrigine 25 mg Tablet0.22USD tablet
Ratio-Lamotrigine 25 mg Tablet0.22USD tablet
Lamictal 5 mg Chewable Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2277722 No2001-03-272012-01-29Canada
US5698226 No1995-07-292012-07-29Us
US7919115 No2009-01-042029-01-04Us
US8637512 No2008-06-142028-06-14Us
US8840925 No2008-07-022028-07-02Us
US9144547 No2003-09-222023-09-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point216-218 °C (uncorr)Not Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.488 mg/mLALOGPS
logP1.87ALOGPS
logP1.93ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.98ChemAxon
pKa (Strongest Basic)5.87ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.71 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity66.62 m3·mol-1ChemAxon
Polarizability23.1 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassHalobenzenes
Direct ParentDichlorobenzenes
Alternative Parents
Substituents
  • 1,2-dichlorobenzene
  • Aminotriazine
  • 1,2,4-triazine
  • Imidolactam
  • Triazine
  • Primary aromatic amine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Primary amine
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
Gene Name:
SCN2A
Uniprot ID:
Q99250
Molecular Weight:
227972.64 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lipkind GM, Fozzard HA: Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol. 2005 Dec;68(6):1611-22. Epub 2005 Sep 20. [PubMed:16174788 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A4
Uniprot ID:
P22310
Molecular Weight:
60024.535 Da
References
  1. Argikar UA, Senekeo-Effenberger K, Larson EE, Tukey RH, Remmel RP: Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica. 2009 Nov;39(11):826-35. doi: 10.3109/00498250903188985. [PubMed:19845433 ]
  2. Chen H, Yang K, Choi S, Fischer JH, Jeong H: Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos. 2009 Sep;37(9):1841-7. doi: 10.1124/dmd.109.026609. Epub 2009 Jun 22. [PubMed:19546240 ]
  3. Argikar UA, Remmel RP: Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63. doi: 10.1080/00498250902745082. [PubMed:19387891 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Argikar UA, Remmel RP: Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63. doi: 10.1080/00498250902745082. [PubMed:19387891 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11. [PubMed:18824002 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 06, 2016 02:41